NKgen Biotech Administers First Troculeucel Dose to Stroke Patient
NKGen Biotech administered its expanded autologous NK cell therapy, troculeucel, to a stroke patient under an FDA-cleared compassionate use...
Jon Napitupulu
Oryzon Defines Phase III Trial Endpoints for Agitation & Aggression in BPD
Oryzon Genomics has established primary and key secondary endpoints for its Phase III clinical trial of vafidemstat for Borderline...
Spectral Medical’s Tigris Trial Update
Spectral Medical Inc. (TSX: EDT) announced an update on its Tigris Phase 3 trial, which is evaluating Polymyxin B...
MBX Biosciences Completes Avail™ Phase 2 Trial Enrollment
MBX Biosciences completed enrollment in its Phase 2 Avail™ trial of canvuparatide, a parathyroid hormone (PTH) prodrug for chronic...
Aura Biosciences NMIBC Data at EAU Congress
Aura Biosciences announced Phase 1 data from its trial of bel-sar (AU-011) for non-muscle invasive bladder cancer (NMIBC) will...
Voyager Reports Positive Topline Anti-Tau Antibody Data, Initiates Next Trial
Voyager Therapeutics announced positive topline data from its single ascending dose (SAD) trial of VY7523, an investigational anti-tau antibody...
Traws Pharma Reports Positive Bird Flu Results for Tivoxavir
Traws Pharma announced positive topline results from a ferret study of tivoxavir marboxil, a single-dose oral antiviral for bird...
Deucrictibant Data at AAAAI/WAO 2025: HAE Prevention & Treatment
Pharvaris released positive long-term data for its oral bradykinin B2 receptor antagonist, deucrictibant, at the 2025 AAAAI/WAO Joint Congress....
Apg990 Interim Phase 1 Results Show Potential for Maintenance Dosing
Apogee Therapeutics announced positive interim Phase 1 results for APG990, a novel, half-life extended OX40L antibody, demonstrating an approximately...
Lexicon Announces Pilavapan Results for Diabetic Nerve Pain
Lexicon Pharmaceuticals will announce topline results from its Phase 2b PROGRESS study of pilavapadin (LX9211) for diabetic peripheral neuropathic...